Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

54.5 (USD) • At close February 4, 2025
Bedrijfsnaam Tarsus Pharmaceuticals, Inc.
Symbool TARS
Munteenheid USD
Prijs 54.5
Beurswaarde 2,083,366,050
Dividendpercentage 0%
52-weken bereik 20.082 - 57.14
Industrie Biotechnology
Sector Healthcare
CEO Dr. Bobak R. Azamian M.D.
Website https://www.tarsusrx.com

An error occurred while fetching data.

Over Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to

Vergelijkbare Aandelen

AxoGen, Inc. logo

AxoGen, Inc.

AXGN

18.08 USD

ADMA Biologics, Inc. logo

ADMA Biologics, Inc.

ADMA

16.9 USD

Akoya Biosciences, Inc. logo

Akoya Biosciences, Inc.

AKYA

2.62 USD

Protagonist Therapeutics, Inc. logo

Protagonist Therapeutics, Inc.

PTGX

37.58 USD

Sight Sciences, Inc. logo

Sight Sciences, Inc.

SGHT

2.8 USD

OrganiGram Holdings Inc. logo

OrganiGram Holdings Inc.

OGI

1.51 USD

Agenus Inc. logo

Agenus Inc.

AGEN

3.5 USD

Repare Therapeutics Inc. logo

Repare Therapeutics Inc.

RPTX

1.19 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)